Untitled

Lyons, Jack D.; Alibazoglu, Buket; Harris, Jules E.; Ali, Amjad; Hollinger, Edward F.

doi:10.1097/00003072-200103000-00010

Cited by 4 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There seems to be some suggestion that patients who have a primary that is in the tail of the pancreas are more likely to develop bone metastasis (13). Bone surveys using standard roentgenograms, CT scans, MRIs, and positron emission topographic (PET) scans have been used to detect skeletal metastases in pancreatic cancer (14)(15)(16)(17). It seems that no imaging modality appears to have a superior detection rate.…”

Section: Introductionmentioning

confidence: 99%

Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis

Zhang

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThe overall survival (OS) of pancreatic cancer (PC) patients with bone metastasis (BM) is extremely low, and it is pretty hard to treat bone metastasis. However, there are currently no effective nomograms to predict the diagnosis and prognosis of pancreatic cancer with bone metastasis (PCBM). Therefore, it is of great significance to establish effective predictive models to guide clinical practice.MethodsWe screened patients from Surveillance Epidemiology and End Results (SEER) database between 2010 and 2016. The independent risk factors of PCBM were identified from univariable and multivariable logistic regression analyses, and univariate and multivariate Cox proportional hazards regression analyses were used to determine independent prognostic factors affecting the prognosis of PCBM. In addition, two nomograms were constructed to predict the risk and prognosis of PCBM. We used the area under the curve (AUC), C-index and calibration curve to determine the predictive accuracy and discriminability of nomograms. The decision curve analysis (DCA) and Kaplan-Meier(K-M) survival curves were employed to further confirm the clinical effectiveness of the nomogram.ResultsMultivariable logistic regression analyses revealed that risk factors of PCBM included age, primary site, histological subtype, N stage, radiotherapy, surgery, brain metastasis, lung metastasis, and liver metastasis. Using Cox regression analyses, we found that independent prognostic factors of PCBM were age, race, grade, histological subtype, surgery, chemotherapy, and lung metastasis. We utilized nomograms to visually express data analysis results. The C-index of training cohort was 0.795 (95%CI: 0.758-0.832), whereas that of internal validation cohort was 0.800 (95%CI: 0.739-0.862), and the external validation cohort was 0.787 (95%CI: 0.746-0.828). Based on AUC of receiver operating characteristic (ROC) analysis, calibration plots, and decision curve analysis (DCA), we concluded that the risk and prognosis model of PCBM exhibits excellent performance.ConclusionNomogram is sufficiently accurate to predict the risk and prognostic factors of PCBM, allowing for individualized clinical decisions for future clinical work.

show abstract

Section: Introductionmentioning

confidence: 99%

Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis

Zhang

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Pearls and pitfalls of imaging metastatic disease from pancreatic adenocarcinoma: a systematic review

Zaheer

Wadhwa

et al. 2015

Clinical Imaging

View full text Add to dashboard Cite

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro

et al. 2003

View full text Add to dashboard Cite

Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients. We investigated the in vitro activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer (PC) cell lines (BxPC-3, CFPAC-1 and PANC-1). Pancreatic cancer frequently has a dysregulated p21 ras pathway and therefore appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21 ras . We found that ZOL induces growth inhibition (IC 50 :10 -50 mM) and apoptotic death of PC cells. The proapoptotic effect was correlated to cleavage/ activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3. Moreover, we studied the p21 ras signalling in cells exposed to ZOL and detected a reduction of p21 ras and Raf-1 content and functional downregulation of the terminal enzyme ERK/ MAPkinase and of the pKB/Akt survival pathway. Finally, we observed that ZOL induces significant cytoskeletal rearrangements. In conclusion, we demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival pathways downstream to p21 ras . These findings might be relevant for expanding application of BPs in cancer treatment.

show abstract

Untitled

Cited by 4 publications

References 6 publications

Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis

Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis

Pearls and pitfalls of imaging metastatic disease from pancreatic adenocarcinoma: a systematic review

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro

Contact Info

Product

Resources

About